SCHEMBL2480192

SCHEMBL2480192

Nc1cccc(-c2nn3ccsc3c2-c2ccncc2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.40
TP53 P04637 1/20 0.40
CYP17A1 P05093 2/20 0.38
CYP3A4 P08684 2/20 0.38
CYP19A1 P11511 2/20 0.38
CYP11B1 P15538 2/20 0.38
CYP11B2 P19099 2/20 0.38
PIK3CD O00329 1/20 0.37
PIK3CB P42338 1/20 0.37
PIK3CG P48736 1/20 0.37
MAPK14 Q16539 6/20 0.36
EGFR P00533 1/20 0.36
RAF1 P04049 1/20 0.36
ADORA3 P0DMS8 1/20 0.36
ADORA2A P29274 1/20 0.36
ADORA2B P29275 1/20 0.36
ADORA1 P30542 1/20 0.36
GSK3B P49841 1/20 0.36
MEN1 O00255 1/20 0.36
PSIP1 O75475 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2477533 0.85 FYN (0.42) CYP17A1CYP3A4CYP19A1CYP11B1CYP11B2
SCHEMBL2478578 0.82 MAPK14 (0.47) LMNATP53CYP19A1MAPK14RAF1
SCHEMBL2477772 0.72 BRAF (0.47) TP53MAPK14EGFRBRAFKDR
SCHEMBL2477784 0.72 BRAF (0.41) CYP3A4CYP19A1PIK3CDPIK3CBPIK3CG
SCHEMBL2480578 0.72 SCN5A (0.47) LMNABRAF
SCHEMBL2477136 0.71 L3MBTL1 (0.48) LMNATP53MAPK14MEN1ALDH1A1
SCHEMBL2479812 0.70 SIRT1 (0.31) MAPK14EGFRRAF1ADORA3ADORA2A
SCHEMBL2477041 0.70 MPO (0.39) CYP17A1CYP3A4CYP19A1CYP11B1CYP11B2
SCHEMBL2478554 0.69 CYP17A1 (0.37) CYP17A1CYP3A4CYP19A1CYP11B1CYP11B2
SCHEMBL2477754 0.68 SMN1; SMN2 (0.46) TP53MEN1TSHRALDH1A1BRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8524707-B2 Bicyclic pyrazoles as protein kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2013-09-03 US disclosed
EP-2373664-B1 BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2013-06-12 EP disclosed
US-20110257165-A1 BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-10-20 US disclosed
EP-2373664-A1 BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS Nerviano Medical Sciences S.r.l. (IT) 2011-10-12 EP disclosed
WO-2010070060-A1 BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2010-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110257165-A1 BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS MAP3K19, MAP4K3, MAP3K15 LMNA 3683/4885TP53 403/4885CYP17A1 2711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.